Specifically, among NSCLC patients treated with anti-PD-1, higher baseline sPD-L1 levels correlated with a worse response rate and a shorter time to treatment failure (median: 1.48 vs 5.36 months) [76]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.